Asia Pacific stem cell therapy market was valued at USD 1,453.61 Mn in 2022 and is projected to reach USD 3,420.05 Mn by 2031, growing at a CAGR of 10.29% between 2023 and 2031.
Request Sample Copy of Research Report @ https://www.astuteanalytica.com/request-sample/asia-pacific-stem-cell-therapy-market
A promising therapeutic approach for the treatment of numerous chronic and life-threatening disorders has emerged: stem cell therapy. Due to a number of factors, including rising public awareness of the therapeutic benefits of stem cell therapy, technological advancements, partnerships between academia and business, and supportive government initiatives, the stem cell therapy market is experiencing significant growth in the Asia-Pacific region. Also, the area is home to a number of top stem cell research organizations and businesses, making it a desirable market for stem cell therapy.
Rising Demand for Stem Cells for Medical Goals: Many different medical illnesses, including cancer, autoimmune diseases, and blood disorders, can be treated with stem cells. The demand for stem cell therapy is likely to rise as these illnesses grow more common.
Growing Number of Cell Therapy Production Facilities: As more businesses enter the stem cell therapy industry, production capacity, and availability have improved, making stem cell therapy more accessible and appealing to customers.
Increasing Funding for Stem Cell Research: Governments, businesses, and investors have pledged to support stem cell research materially and legally. This has made it possible for researchers to create treatments that are more effective and efficient, which has increased the demand for stem cell therapy.
The Asia Pacific stem cell therapy market is also growing owing to a number of other factors, such as the region’s large aging population, the rising desire for novel and cutting-edge medical treatments, and increasing public understanding of the advantages of stem cell therapy. The rising prevalence of chronic conditions, including diabetes, heart disease, and Alzheimer’s disease is also a factor in the rising need for stem cell therapy therapies.
Embryonic Stem Cell-related Ethical Issues
Embryonic stem cell research is a difficult and emotionally sensitive subject that has recently generated various ethical questions. Much discussion has been aroused by the use of embryonic stem cells in research and therapy, both within the scientific community and among the general public. On the one hand, these cells offer significant potential for treating conditions that are currently incurable. Nonetheless, a lot of people contend that its use is immoral because it results in the amputation of human embryos.
Three key countries supporting the growth of the Asia Pacific stem cell therapy market: China, Japan, and Australia.
China is the market leader for stem cell therapy in the Asia Pacific region. However, several other nations also dominate this market. The Chinese government has developed numerous research institutions and production facilities, in addition to making large investments in the nation’s stem cell market. Thus, the Chinese Academy of Sciences and the Shanghai Institute of Materia Medica are two well-known stem cell research institutions that have grown. These investments have made China one of the Asia Pacific region’s most alluring markets for stem cell therapy.
In India, the launch of National Guidelines for Stem Cell Research in 2020 has aided in the market expansion for stem cell therapies. In an effort to encourage the growth of the stem cell industry, the government has also introduced a number of programs, such as the “Stem Cell Initiative Scheme” in 2019. India has emerged as a desirable destination for investments in the sector thanks to its emphasis on stem cell research and therapy.
Japan has put policies into place to encourage the growth and commercialization of stem cell research. This covers financial plans, tax breaks, and research funds. The nation has built a number of state-of-the-art clinical trial facilities and is substantially funding regenerative medicine research. As a result of these initiatives, Japan is now the Asia Pacific region’s center for stem cell therapy.
The stem cell market has expanded in Australia as well. The government has built a number of top-tier stem cell research institutions, like the Centre for Stem Cell Systems in Melbourne, to support the industry growth. In the Asia Pacific area, the nation represents a viable market for stem cell therapy since it is making significant investments in efforts to create stem cell products for commercial use.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.astuteanalytica.com/industry-report/asia-pacific-stem-cell-therapy-market
Anterogen Co. Ltd., Astellas Pharma Inc., Brainstorm Cell Ltd, Fujifilm Holding Corporation, and MEDIPOST Co. Ltd. are all significant competitors in the market, and together they account for over 30% of the market share in this area. In order to further solidify their market position, these businesses are making significant investments in research and development projects that will result in the creation of new goods and technology. Government efforts and legislation is rising the development of the stem cell therapy market in the region. Also, the industry will be boosted by rising disposable incomes and public knowledge of stem cell treatments.
Therapy Type Overview
In 2022, the allogeneic stem cell therapy segment recorded a revenue of US$ 839.17 million in the global Asia Pacific stem cell therapy industry. The development of stem cell banking and the absence of difficulties are two aspects that have contributed to the segment’s expansion. Also, there have been more cell therapy businesses that are concentrating on the creation of allogeneic stem cell treatments.
Cell Source Overview
In 2022, the adipose tissue-derived MSCs segment dominated the APAC stem cell therapy industry, recording a share of 49%, and is likely to increase at a CAGR of 10.74% throughout the forecast period. The increased use of MSCs produced from adipose tissue for various therapeutic purposes is driving up demand for them.
By Therapy Type:
- Autologous Stem Cell Therapy
- Allogeneic Stem Cell Therapy
By Product segment:
- Adult Stem Cells (ASCs)
- Human Embryonic Stem Cells (HESCs)
- Induced Pluripotent Stem Cells (iPSCs)
- Very Small Embryonic Like Stem Cells
By Cell source:
- Adipose tissue-derived MSCs
- Bone marrow-derived MSCs
- Placental/umbilical cord-derived MSCs
- Other Cell Sources
- Cell Acquisition
- Cell Production
- Expansion and Sub-Culture
- Musculoskeletal Disorders
- Wounds and Injuries
- Acute Graft-Versus-Host Disease (AGVHD)
- Gastrointestinal Diseases
- Cardiovascular Diseases
- Inflammatory & Autoimmune Diseases
- Neurological Disorders
- Research institutes
- Surgical institutes
- Australia & New Zealand
- South Korea
- Rest of Asia Pacific
Directly Purchase a copy of report with TOC @ https://www.astuteanalytica.com/inquire-before-purchase/asia-pacific-stem-cell-therapy-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Follow US: LinkedIn | Twitter